Shopping Cart
Remove All
Your shopping cart is currently empty
ZG-2686
Catalog No. T213885 Copy Product Info
🥰Excellent
ZG-2686 is a potent and selective agonist of HIF-2α with an EC50 of 0.25 µM, demonstrating selectivity for PHD2. It binds to a specific internal cavity of HIF-2α, forming hydrogen bonds through structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances its transcriptional activity. The compound acts synergistically with Vadadustat to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 is applicable for renal anemia research.
ZG-2686
Copy Product Info🥰Excellent
Catalog No. T213885
ZG-2686 is a potent and selective agonist of HIF-2α with an EC50 of 0.25 µM, demonstrating selectivity for PHD2. It binds to a specific internal cavity of HIF-2α, forming hydrogen bonds through structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances its transcriptional activity. The compound acts synergistically with Vadadustat to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 is applicable for renal anemia research.
ZG-2686
Cas No. 1795110-22-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ZG-2686 is a potent and selective agonist of HIF-2α with an EC50 of 0.25 µM, demonstrating selectivity for PHD2. It binds to a specific internal cavity of HIF-2α, forming hydrogen bonds through structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances its transcriptional activity. The compound acts synergistically with Vadadustat to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 is applicable for renal anemia research. |
| Targets&IC50 | HIF2α:0.25 μM (EC50) |
| In vitro | ZG-2686 demonstrates excellent in vitro metabolic stability in rat plasma and liver microsomes. When combined with Vadadustat (10-20 μM; 12 hours), ZG-2686 synergistically enhances the levels of HIF-2α-dependent EPO mRNA in Hep3B cells. |
| In vivo | ZG-2686 (10 and 20 mg/kg; intraperitoneal injection; single dose) shows limited efficacy in inducing EPO on its own in vivo, but it can enhance EPO expression in C57BL/6 mice when used in synergy with Vadadustat. |
| Molecular Weight | 317.15 |
| Formula | C13H9BrN4O |
| Cas No. | 1795110-22-3 |
| Smiles | O=C(NC1=NNC=2N=CC=CC21)C3=CC=C(Br)C=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ZG-2686 | purchase ZG-2686 | ZG-2686 cost | order ZG-2686 | ZG-2686 in vivo | ZG-2686 in vitro | ZG-2686 formula | ZG-2686 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.